Medtronic Voluntary Response To MIS Data Integrity Problems Averts AIP
This article was originally published in The Gray Sheet
Executive SummaryMedtronic's voluntary actions to ensure data integrity in premarket submissions from its Micro Interventional Systems unit appears to have helped avert imposition of FDA's application integrity policy.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.